J&J/Scios Natrecor Labeling Change Includes Expanded Mortality Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA does not believe a "Dear Doctor" letter or advisory committee review are warranted at this time. The new labeling reports 30-day and 180-day mortality risks for Natrecor compared to active controls in all randomized trials of the CHF therapy.